(c) a DNA consisting of the nucleotide sequence identical to the sequence of (a) or (b) above except for one or several nucleotides;
(d) an RNA that is a transcript of (a), (b) or (c) above; and
(e) a DNA or RNA consisting of the sequence that can bind to the sequence of (a) above by base pairing.

6. The method according to Claim 1, wherein the cell is a strongly APES-expressing cell.

7. The method according to Claim 1, wherein the cell into which the APES has been artificially introduced is a cell transfected with the APES.

8. The method according to Claim 1, wherein the cell into which the APES has been artificially introduced is a cell in which the transcription of endogenous APES has been activated.

9. The method according to Claim 1, wherein a DNA encoding a taurine transporter has been further introduced into the cell.

10. The method according to Claim 1, wherein a DNA encoding cysteine sulfinic acid decarboxylase has been further introduced into the cell.

11. The method according to Claim 1, wherein a DNA encoding alanine transferase has been further introduced into the cell.

12. The method according to Claim 1, wherein the cell is a Chinese hamster ovary cell.

13. A method of producing a pharmaceutical comprising the step of formulating the polypeptide produced by the method according to any of Claims 1 to 12 into a pharmaceutical composition.

14. A nucleic acid molecule that consists of any of the following nucleotide sequences and has APES activity:
(a) a DNA consisting of the nucleotide sequence of any of SEQ ID NOs: 2, 4 to 16 and 29;
(b) a DNA consisting of the nucleotide sequence identical to the sequence of any of SEQ ID NOs: 1

(c) a DNA consisting of the nucleotide sequence identical to the sequence of (a) or (b) above except for one or several nucleotides;
(d) an RNA that is a transcript of (a), (b) or (c) above; and
(e) a DNA or RNA consisting of the sequence that can bind to the sequence of (a) above by base pairing.

6. The method according to Claim 1, wherein the cell is a strongly APES-expressing cell.

7. The method according to Claim 1, wherein the cell into which the APES has been artificially introduced is a cell transfected with the APES.

8. The method according to Claim 1, wherein the cell into which the APES has been artificially introduced is a cell in which the transcription of endogenous APES has been activated.

9. The method according to Claim 1, wherein a DNA encoding a taurine transporter has been further introduced into the cell.

10. The method according to Claim 1, wherein a DNA encoding cysteine sulfinic acid decarboxylase has been further introduced into the cell.

11. The method according to Claim 1, wherein a DNA encoding alanine transferase has been further introduced into the cell.

12. The method according to Claim 1, wherein the cell is a Chinese hamster ovary cell.

13. A method of producing an antibody-containing pharmaceutical, the method comprising:
producing an antibody according to the method of any one of claims 1 to 12, and
formulating said antibody into a pharmaceutical composition by mixing said antibody with a pharmaceutically acceptable carrier or additive.

14. A nucleic acid molecule that consists of any of the following nucleotide sequences and has APES activity:
(a) a DNA consisting of the nucleotide sequence of any of SEQ ID NOs: 2, 4 to 16 and 29;
(b) a DNA consisting of the nucleotide sequence identical to the sequence of any of SEQ ID NOs: 1